Precipio (NASDAQ:PRPO) Stock Passes Below 200-Day Moving Average – Should You Sell?

Precipio, Inc. (NASDAQ:PRPO) shares crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $25.17 and traded as low as $22.95. Precipio shares last traded at $25.24, with a volume of 170,506 shares.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on PRPO shares. Wall Street Zen cut Precipio from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precipio in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

Precipio Stock Performance

The stock has a market cap of $45.18 million, a price-to-earnings ratio of -53.70 and a beta of 1.27. The company’s 50-day simple moving average is $24.42 and its 200-day simple moving average is $25.17. The company has a quick ratio of 1.33, a current ratio of 1.56 and a debt-to-equity ratio of 0.05.

Precipio (NASDAQ:PRPO) last announced its earnings results on Thursday, May 14th. The biotechnology company reported ($0.81) earnings per share (EPS) for the quarter. Precipio had a negative return on equity of 6.73% and a negative net margin of 3.57%.The company had revenue of $6.71 million for the quarter.

Institutional Investors Weigh In On Precipio

Several hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC grew its stake in Precipio by 33.1% in the first quarter. Renaissance Technologies LLC now owns 19,300 shares of the biotechnology company’s stock valued at $482,000 after purchasing an additional 4,800 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Precipio by 5.1% in the fourth quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock worth $377,000 after buying an additional 789 shares during the last quarter. Finally, Susquehanna International Group LLP acquired a new stake in shares of Precipio in the third quarter worth about $194,000. 10.45% of the stock is owned by hedge funds and other institutional investors.

Precipio Company Profile

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.